$MRK Analyst Blog


Merck (MRK) Beats on Q1 Earnings & Revenues, Ups View – Analyst Blog

Merck & Co. MRK reported first quarter 2015 earnings of 85 cents per share, beating the Zacks Consensus Estimate of 75 cents. Earnings, however, declined 3.4% from the year-ago period.

 Revenues for the quarter declined 8.2% to $9.425 billion but surpassed the Zacks Consensus Estimate of $8.98 billion. While currency movement negatively impacted revenues by 5%, patent expiries and divestitures impacted revenues by net 9%. This was partially offset by the Cubist acquisition.

The Quarter in Detail

Merck’s Pharmaceutical segment posted revenues of $8.3 billion, down 2%. Currency movement negatively impacted revenues by 7%. Cubist products boosted sales by $208 million including Cubicin sales of $182 million.

Products like Janumet, Januvia and Simponi performed well. However, this was offset by lower revenues of Remicade, Zetia/Vytorin, Isentress, Gardasil, Nasonex, PegIntron, Cozaar/Hyzaar and Temodar.

Keytruda, launched recently, brought in sales of $83 million in the first quarter of 2015, up from $50 million in the fourth quarter of 2014.

Merck’s animal health segment posted revenues of $829 million, up 2% benefiting from higher companion animal product sales.

Marketing and administrative expenses declined 13.2% to $2.3 billion in the first quarter of 2015. R&D spend increased 9.7% to $1.7 billion in the first quarter of 2015.

Earnings Guidance Up

Merck raised its 2015 earnings guidance to $3.35 and $3.48 per share from the earlier guidance of $3.32 – $3.47 per share. Revenue guidance remains unchanged at $38.3 billion – $39.8 billion. Currency is expected to impact earnings by 27 cents and revenues by about $2.8 billion. Revenues will also be impacted by about $1 billion due to net lost sales from acquisitions and divestitures.

Meanwhile, Merck expects marketing and administrative spend to decline from 2014 levels. However, R&D spend is expected to be slightly above 2014 levels. The company spent $6.5 billion and $10.9 billion on R&D and marketing and administrative matters, respectively, in 2014.

Our Take

Merck’s first quarter results were better-than-expected despite headwinds like generic competition and unfavorable currency movement. Moreover, the company raised its earnings outlook for 2015 at a time when other health care companies like Pfizer PFE lowered their 2015 outlook to reflect the impact of currency movement. Meanwhile, Merck continues to progress with its pipeline.


Please enter your comment!
Please enter your name here